Showing 181 - 200 results of 10,020 for search '(( significantly we decrease ) OR ( significantly associated decrease ))', query time: 0.48s Refine Results
  1. 181

    Future research directions. by Martha R. Smith (20410184)

    Published 2024
    “…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”
  2. 182

    PRISMA flow diagram. by Martha R. Smith (20410184)

    Published 2024
    “…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”
  3. 183

    S9 File - by Martha R. Smith (20410184)

    Published 2024
    “…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”
  4. 184

    S7 File - by Martha R. Smith (20410184)

    Published 2024
    “…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”
  5. 185

    Participant characteristics of included studies. by Martha R. Smith (20410184)

    Published 2024
    “…Five of the 11 studies that evaluated hepatic steatosis reported an absolute decrease of 1% to 3%. In the nine studies that evaluated liver chemistry, no significant changes were observed.…”
  6. 186
  7. 187
  8. 188

    GLM models for predictors of monthly HIV costs. by Drew B. Cameron (10687420)

    Published 2024
    “…The integration of care for these conditions presents an opportunity to achieve efficiencies in delivery as well as decrease overall costs for patients. This study aims to build evidence on the burden of current out-of-pocket costs of care among HIV-HTN co-morbid patients.…”
  9. 189

    Median cost (USD) per visit breakdown. by Drew B. Cameron (10687420)

    Published 2024
    “…The integration of care for these conditions presents an opportunity to achieve efficiencies in delivery as well as decrease overall costs for patients. This study aims to build evidence on the burden of current out-of-pocket costs of care among HIV-HTN co-morbid patients.…”
  10. 190
  11. 191
  12. 192
  13. 193
  14. 194
  15. 195
  16. 196
  17. 197

    Data Sheet 1_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  18. 198

    Data Sheet 2_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  19. 199

    Data Sheet 3_Case report: Significant lesion reduction and neural structural changes following ibogaine treatments for multiple sclerosis.docx by David Qixiang Chen (8198265)

    Published 2025
    “…Ibogaine, a psychoactive alkaloid, has been proposed as a potential neuroregenerative agent due to its multifaceted pharmacological profile. We present two case studies of MS patients who underwent a novel ibogaine treatment, highlighting significant neuroimaging changes and clinical improvements. …”
  20. 200